Brainstorm cell therapeutics announces third quarter 2022 financial results and provides a corporate update

Brainstorm to request type a meeting with fda to facilitate nurown's advancement following receipt of a refusal to file letter regarding the company's new biologics license application conference call and webcast at 8:00 a.m. eastern time today new york , nov. 14, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended september 30, 2022, and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking